Tratamento
CagriSema: What 2026 Data Reveals About the Future of Obesity Treatment In 2024, when the first FLOW trial results were presented, the medical community needed a moment to absorb the magnitude of the impact. An average body weight reduction above 20%, with significant cardiovascular benefits.
Tirzepatide vs Semaglutide: What the SURMOUNT-5 Trial Actually Tells Us If you have been following the world of weight loss medications, you have probably seen the headlines. Tirzepatide beats semaglutide. The numbers are striking, the buzz is real, and a lot of people are left wondering whi.
Retatrutide: What We Know About the New Drug That's Changing the Weight Loss Game The medical community has never seen anything quite like it. Retatrutide, developed by Eli Lilly, is the first triple-receptor peptide agonist targeting GLP-1, GIP, and glucagon approved for obesity treatment.
Stopping GLP-1: what happens to your weight when you quit Anyone who has tried to lose weight with the help of medication knows that the hardest phase is not starting. When you finally reach a weight that seemed impossible, the urge is to enjoy the result and move on. But what if stopping th.
GLP-1 Biosimilars: What You Need to Know About Copies, Patents, and International Regulation When semaglutide started appearing everywhere, a question began circulating among patients and healthcare professionals: are the copies really equivalent to the original. The short answer is: it depen.
Plateau with GLP-1: Why Your Weight Stalls and What to Do When You Feel Like Nothing Works You reach week twelve and the scale simply will not budge. You did everything right, ate well, exercised, took your medication on time. But the number on the display does not change. This has a name:.
Saxenda vs Ozempic: A Comparison of Adherence and Cost in Brazil Anyone starting research on weight loss medications quickly comes across these two names. Saxenda and Ozempic are among the most discussed in doctors' offices and online conversations. But each one represents a very different a.
CAGRISEMA vs Ozempic: Everything You Need to Know About This New GLP-1 Combination The world of weight loss medication keeps evolving, and a new name has been making the rounds lately. Cagrisema, a combination of cagrilintide and semaglutida, recently posted some impressive clinical trial num.
Retatrutide: What the TRIUMPH-2 Trial Reveals About the Future of Weight Loss Medications The medical community has never seen anything like it. When Eli Lilly announced the results of the TRIUMPH-2 trial, the numbers caught attention worldwide. Retatrutide, a molecule that targets three rec.
GLP-1 After Bariatric Surgery: What No One Tells You About Post-Op Optimization Bariatric surgery is not the end of the road. It is just the beginning of a stage that requires attention, knowledge, and the right tools to keep the results going long-term. Many people believe that after the pr.
